Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 333
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines A Scientific Workshop Agenda INSTITUTE OF MEDICINE NATIONAL ACADEMY OF SCIENCES Committee on Health Effects Associated with Exposures During the Gulf War June 14–15, 1999 Cecil and Ida Green Building, Room 126 2001 Wisconsin Avenue N.W., Washington, D.C. MONDAY, JUNE 14, 1999 8:15–8:30 a.m. Opening Remarks Harold Sox, M.D. (Chair) 8:30–9:00 a.m. War Syndromes and Their Evaluation Craig Hyams, M.D., M.P.H. Naval Medical Research Center 9:00–10:00 a.m. Epidemiologic Studies on Gulf War Veterans 9:00–9:30 a.m. The Iowa Persian Gulf Study Bradley Doebbeling, M.D. University of Iowa College of Medicine 9:30–10:00 a.m. Health Study of Canadian Forces Personnel Lesbia F. Smith, M.D. Department of Public Health Sciences, University of Toronto 10:00–10:30 a.m. Health Effects of Depleted Uranium David McClain, Ph.D. Armed Forces Radiobiology Research Institute 10:30–11:15 a.m. Pentavalent Botulinum Toxoid: Human Clinical Safety—30 Years of Experience at a Biological Laboratory

OCR for page 333
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines   Anthrax Vaccine: Human Safety Data—25 years of Experience at USAMRIID and the Safety of a Recent Human Dose Reduction Study Phillip Pittman, M.D., M.P.H. U.S. Army Medical Research Institute of Infectious Diseases 11:15–11:45 p.m. IOM study Veterans and Agent Orange, Methodology Andrew Olshan, Ph.D. School of Public Health, University of North Carolina at Chapel Hill 11:45–12:15 p.m. Genetic Susceptibility James Hanson, M.D. National Cancer Institute 12:15–12:45 p.m. Lunch 12:45–1:15 p.m. Chemical Interactions: Pyridostigmine Bromide, DEET, and Permethrin Mohamed Abou-Donia, Ph.D. Duke University Medical Center 1:15–1:45 p.m. PB and Growth Hormone Keith Friend, M.D. M.D. Anderson Cancer Center 1:45–2:30 p.m. Biological Effects of Stress William Malarkey, M.D. Ohio State University 2:30–3:30 p.m. Toxicant-Induced Loss of Tolerance Claudia Miller, M.D., M.S. University of Texas Health Science Center at San Antonio 3:30–4:00 p.m. Chemical Interactions Ernest Hodgson, Ph.D. North Carolina State University 4:00–5:00 p.m. Plenary Session 5:00 p.m. Adjourn

OCR for page 333
Gulf War and Health: Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines TUESDAY, JUNE 15, 1999 1:30–2:00 p.m. Exposure Assessment Issues Demetrios Moschandreas, Ph.D. (committee member) Illinois Institute of Technology 2:00–2:30 p.m. Methodological Issues Charles Phelps, Ph.D. (committee member) University of Rochester 2:30–3:00 p.m. Anthrax Vaccine Philip Brachman, M.D. Rollins School of Public Health, Emory University